Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.61 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.48 |
| ▸ | KHK | P50053 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092610 | 0.84 | ULK1 (0.61) | ULK1SCN3ASCN9APSMB8KHK | |
| Hydrochloric Acid SCHEMBL6093765 | 0.76 | EPHX2 (0.58) | ULK1SCN3ASCN9APSMB8SCN5A | |
| SCHEMBL4381414 | 0.76 | HTT (0.49) | — | |
| SCHEMBL4564880 | 0.75 | SCN3A (0.62) | ULK1SCN3ASCN9APSMB8KHK | |
| SCHEMBL7788050 | 0.75 | SCN3A (0.62) | ULK1SCN3ASCN9APSMB8KHK | |
| SCHEMBL8350468 | 0.75 | DHFR (0.54) | DHFR | |
| SCHEMBL3341031 | 0.74 | NPC1 (0.58) | ULK1SCN3ASCN9APSMB8IKBKB | |
| SCHEMBL3343865 | 0.74 | NPC1 (0.58) | ULK1SCN3ASCN9APSMB8IKBKB | |
| SCHEMBL3341023 | 0.74 | NPC1 (0.58) | ULK1SCN3ASCN9APSMB8IKBKB | |
| SCHEMBL20673052 | 0.73 | ULK1 (0.53) | ULK1SCN3ASCN9APSMB8KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112590-B2 | Thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2006-09-26 | — | — | US | disclosed |
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
| EP-1287018-A2 | THROMBIN INHIBITORS | Lek Pharmaceutical and Chemical Co. D.D. (SI) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001085760-A1 | THROMBIN INHIBITORS | LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | ULK1 4703/4885SCN3A 3213/4885SCN9A 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.